Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer

Clinical Prostate Cancer

Volumn 4, Issue 2, 2005, Pages 91-99

  Hawkins, Robert E ^a   Daigneault, Luc ^b   Cowan, Richard ^a   Griffiths, Richard ^a   Panchal, Chandra ^b   Armstrong, Anne ^a   Fenemore, Jackie ^a   Irvine, Alan ^c   Sereda, Kasia ^c   Dulude, Hélène ^b,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c ORION Clinical Services Ltd   (United Kingdom)

^d Procyon Biopharma Inc   (Canada)

Author keywords

Angiogenesis; Dose limiting toxicity; Invasiveness; Matrix metalloproteinase 9

Indexed keywords

GELATINASE B; PCK 3145; PROSTATE SPECIFIC ANTIGEN; PROSTATIC SECRETORY PROTEIN; SYNTHETIC PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BODY BURDEN; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DOSE CALCULATION; DOSE LIMITING TOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EDEMA; EPISTAXIS; FATIGUE; FRACTURE; HEADACHE; HEART ARRHYTHMIA; HEMATURIA; HORMONE RESISTANCE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; ISCHIALGIA; KNEE LIGAMENT INJURY; MALE; METASTASIS; METASTASTIC HORMONE REFRACTORY PROSTATE CANCER; MOOD DISORDER; NAUSEA; PAIN; PROSTATE CANCER; RECTUM FISTULA; RECTUM HEMORRHAGE; SENSORY NEUROPATHY; SPINAL CORD COMPRESSION; STOMATITIS; SYNCOPE; TUMOR GROWTH; TUMOR VOLUME; URINE RETENTION; VOMITING; WOUND INFECTION;

EID: 26944483962     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.016     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward A, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Hanks GE, Krall JM, Hanlon AL, et al. Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 1994; 28:39-45.
3. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152(suppl 2):1850-1857.
4. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002; 7:360-370.
5. Martel CL, Gumerlock PH, Meyers FJ, et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003; 29:171-187.
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
7. Saad F, Gleason DM, Murray R, et al. A randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
8. Hyakutake H, Sakai H, Yogi Y, et al. Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 1993; 22:347-355.
9. Sakai H, Tsurusaki T, Kanda S, et al. Prognostic significance of B-microseminoprotein mRNA expression in prostate cancer. Prostate 1999; 38:278-284.
10. Vanaja DK, Cheville JC, Iturria SJ, et al. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63:3877-3882.
11. Garde S, Sheth A, Porter AT, et al. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate 1993; 22:225-233.
12. Lokeshwar BL, Hurkadli KS, Sheth AR, et al. Human prostatic inhibin suppresses tumour growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res 1993; 53:4855-4859.
13. Shukeir N, Arakelian A, Kadhim S, et al. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003; 63:2072-2078.
14. Shukeir N, Arakelian A, Chen G, et al. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases and malignancy-associated hypercalcemia. Cancer Res 2004; 64:5370-5377.
15. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982:409-417.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
17. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendation from the Prostate-Specific Antigen Working Party. J Clin Oncol 1999; 17:3461-3467.
18. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135-1149.
19. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-2392.
20. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999; 878:212-227.
21. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 1994; 91:4293-4297.
22. Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79:96-101.
23. Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58:1395-1399.
24. Lokeshwar BL. MMP inhibition in prostate cancer. Ann N Y Acad Sci 1999; 878:271-289.
25. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumour cell proliferation in prostate cancer metastasis. J Natl Cancer Inst 2002; 94:17-25.
26. Assikis V, Do KA, Wen S, et al. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Can Res 2004; 10:6770-6778.
27. Kuniyasu H, Troncoso P, Johnston D, et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growdi factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000; 6:2295-2308.
28. Ranuncolo SM, Armanasco E, Cresta C, et al. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognossis in breast cancer patients. Int J Cancer 2003; 106:745-751.
29. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5:149-153.
30. Tutton MG, George ML, Eccles SA, et al. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003; 107:541-550.
31. Panchal C, Hawkins R, Rabbani SA, et al. Development of a novel peptide drug PCK3145 derived from the naturally occurring prostate secretory protein PSP94. Presented at: First International Congress on Natural Peptides to Drugs Meeting; November 30, 2004; Zermatt, Switzerland.